Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
David Schenkein
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Concepts & Ideas
Phenomena
Procedures
Sign-in to see full Profile
Network (preview)
16
Miller, Kenneth
13
Esseltine, Dixie
10
Anderson, Kenneth
8
Irwin, David
7
Jagannath, Sundar
7
Richardson, Paul
6
Barlogie, Bart
5
Boral, Anthony
5
Sprague, Kellie
5
Trehu, Elizabeth
4
Stadtmauer, Edward
4
Singhal, Seema
4
Wright, John
4
Comenzo, Raymond
4
Rajkumar, Vincent
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of David Schenkein (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2008: Davies Angela M; Ruel Christopher; Lara Primo N; Lau Derick H; Gumerlock Paul H; Bold Richard; Shibata Stephen; Lenz Heinz-Josef; Schenkein David P; Gandara David R
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(1):68-74.
-
2007: Richardson Paul G; Sonneveld Pieter; Schuster Michael; Irwin David; Stadtmauer Edward; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Miguel Jesus San; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Alsina Melissa; Rajkumar S Vincent; Lacy Martha; Jakubowiak Andrzej; Dalton William; Boral Anthony; Esseltine Dixie-Lee; Schenkein David; Anderson Kenneth C
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Blood 2007;110(10):3557-60.
-
2007: Mulligan George; Mitsiades Constantine; Bryant Barb; Zhan Fenghuang; Chng Wee J; Roels Steven; Koenig Erik; Fergus Andrew; Huang Yongsheng; Richardson Paul; Trepicchio William L; Broyl Annemiek; Sonneveld Pieter; Shaughnessy John D; Bergsagel P Leif; Schenkein David; Esseltine Dixie-Lee; Boral Anthony; Anderson Kenneth C
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Blood 2007;109(8):3177-88.
-
2007: Strauss Sandra J; Higginbottom Karen; Jüliger Simone; Maharaj Lenushka; Allen Paul; Schenkein David; Lister T Andrew; Joel Simon P
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Cancer research 2007;67(6):2783-90.
-
2006: Hideshima Teru; Neri Paola; Tassone Pierfranchesco; Yasui Hiroshi; Ishitsuka Kenji; Raje Noopur; Chauhan Dharminder; Podar Klaus; Mitsiades Constantine; Dang Lenny; Munshi Nikhil; Richardson Paul; Schenkein David; Anderson Kenneth C
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5887-94.
-
2006: Gerecitano John; Goy Andre; Wright John; MacGregor-Cortelli Barbara; Neylon Ellen; Gonen Mithat; Esseltine Dixie; Boral Anthony; Schenkein David; Busam Klaus; Teruya-Feldstein Julie; Sachs Dana; O'Connor Owen A
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
British journal of haematology 2006;134(4):391-8.
-
2006: Jagannath Sundar; Richardson Paul G; Barlogie Bart; Berenson James R; Singhal Seema; Irwin David; Srkalovic Gordan; Schenkein David P; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Haematologica 2006;91(7):929-34.
-
2006: Stubblefield M D; Slovin S; MacGregor-Cortelli B; Muzzy J; Scher H; Wright J; Esseltine D; Schenkein D; O'Connor O A
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2006;18(5):410-8.
-
2006: Strauss Sandra J; Maharaj Lenushka; Hoare Susan; Johnson Peter W; Radford John A; Vinnecombe Sarah; Millard Lynda; Rohatiner Ama; Boral Anthony; Trehu Elizabeth; Schenkein David; Balkwill Frances; Joel Simon P; Lister T Andrew
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(13):2105-12.
-
2006: Lara Primo N; Koczywas Mariana; Quinn David I; Lenz Heinz Josef; Davies Angela M; Lau Derick H M; Gumerlock Paul H; Longmate Jeff; Doroshow James H; Schenkein David; Kashala Oscar; Gandara David R
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(2):126-34.
-
2005: Ross Jeffrey S; Gray Karen E; Webb Iain J; Gray Gary S; Rolfe Mark; Schenkein David P; Nanus David M; Millowsky Mathew I; Bander Neil H
Antibody-based therapeutics: focus on prostate cancer.
Cancer metastasis reviews 2005;24(4):521-37.
-
2005: Lonial Sagar; Waller Edmund K; Richardson Paul G; Jagannath Sundar; Orlowski Robert Z; Giver Cynthia R; Jaye David L; Francis Dixil; Giusti Sara; Torre Claire; Barlogie Bart; Berenson James R; Singhal Seema; Schenkein David P; Esseltine Dixie-Lee W; Anderson Jessica; Xiao Hugh; Heffner Leonard T; Anderson Kenneth C;
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood 2005;106(12):3777-84.
-
2005: Berenson James R; Jagannath Sundar; Barlogie Bart; Siegel David T; Alexanian Raymond; Richardson Paul G; Irwin David; Alsina Melissa; Rajkumar S Vincent; Srkalovic Gordon; Singhal Seema; Limentani Steven; Niesvizky Ruben; Esseltine Dixie L; Trehu Elizabeth; Schenkein David P; Anderson Kenneth
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Cancer 2005;104(10):2141-8.
-
2005: Richardson Paul Gerard Guy; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Hideshima Teru; Xiao Hugh; Esseltine Dixie; Schenkein David; Anderson Kenneth C;
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Blood 2005;106(9):2977-81.
-
2005: Schenkein David P
Preclinical data with bortezomib in lung cancer.
Clinical lung cancer 2005;7 Suppl 2():S49-55.
-
2005: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; San-Miguel Jesus F; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Dalton William S; Boral Anthony L; Esseltine Dixie L; Porter Jane B; Schenkein David; Anderson Kenneth C;
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
The New England journal of medicine 2005;352(24):2487-98.
-
2005: Jagannath Sundar; Durie Brian G M; Wolf Jeffrey; Camacho Elber; Irwin David; Lutzky Jose; McKinley Marti; Gabayan Eli; Mazumder Amitabha; Schenkein David; Crowley John
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
British journal of haematology 2005;129(6):776-83.
-
2005: Oakervee Heather E; Popat Rakesh; Curry Nicola; Smith Pat; Morris Curly; Drake Mary; Agrawal Samir; Stec Jim; Schenkein David; Esseltine Dixie-Lee; Cavenagh Jamie D
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
British journal of haematology 2005;129(6):755-62.
-
2005: O'Connor Owen A; Wright John; Moskowitz Craig; Muzzy Jamie; MacGregor-Cortelli Barbara; Stubblefield Michael; Straus David; Portlock Carol; Hamlin Paul; Choi Elizabeth; Dumetrescu Otila; Esseltine Dixie; Trehu Elizabeth; Adams Julian; Schenkein David; Zelenetz Andrew D
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):676-84.
-
2005: Goy Andre; Younes Anas; McLaughlin Peter; Pro Barbara; Romaguera Jorge E; Hagemeister Frederick; Fayad Luis; Dang Nam H; Samaniego Felipe; Wang Michael; Broglio Kristine; Samuels Barry; Gilles Frederic; Sarris Andreas H; Hart Susan; Trehu Elizabeth; Schenkein David; Cabanillas Fernando; Rodriguez Alma M
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):667-75.
-
2004: Schenkein David P
Use of proteasome inhibition in the treatment of lung cancer.
Clinical lung cancer 2004;6 Suppl 2():S89-96.
-
2004: O'Connor Owen; Wright John; Moskowitz Craig H; Muzzy Jamie; MacGregor-Cortelli Barbara; Hamlin Paul; Straus David; Trehu Elizabeth; Schenkein David P; Zelenetz Andrew D
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 4():S21-2.
-
2004: Ross Jeffrey S; Schenkein David P; Pietrusko Robert; Rolfe Mark; Linette Gerald P; Stec James; Stagliano Nancy E; Ginsburg Geoffrey S; Symmans W Fraser; Pusztai Lajos; Hortobagyi Gabriel N
Targeted therapies for cancer 2004.
American journal of clinical pathology 2004;122(4):598-609.
-
2004: Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson P G; Niesvizky R; Alexanian R; Limentani S A; Alsina M; Adams J; Kauffman M; Esseltine D-L; Schenkein D P; Anderson K C
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
British journal of haematology 2004;127(2):165-72.
-
2004: Ross Jeffrey S; Schenkein David P; Kashala Oscar; Linette Gerald P; Stec James; Symmans W Fraser; Pusztai Lajos; Hortobagyi Gabriel N
Pharmacogenomics.
Advances in anatomic pathology 2004;11(4):211-20.
-
2004: Miller K B; Roberts T F; Chan G; Schenkein D P; Lawrence D; Sprague K; Gorgun G; Relias V; Grodman H; Mahajan A; Foss F M
A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease.
Bone marrow transplantation 2004;33(9):881-9.
-
2003: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Alexanian Raymond; Siegel David; Orlowski Robert Z; Kuter David; Limentani Steven A; Lee Stephanie; Hideshima Teru; Esseltine Dixie-Lee; Kauffman Michael; Adams Julian; Schenkein David P; Anderson Kenneth C
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
-
2003: Ross Jeffreys; Gray Karen; Schenkein David; Greene Barry; Gray Gary S; Shulok Jeanine; Worland Peter J; Celniker Abbie; Rolfe Mark
Antibody-based therapeutics in oncology.
Expert review of anticancer therapy 2003;3(1):107-21.
-
2001: Narayanasami U; Kanteti R; Morelli J; Klekar A; Al-Olama A; Keating C; O'Connor C; Berkman E; Erban J K; Sprague K A; Miller K B; Schenkein D P
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.
Blood 2001;98(7):2059-64.
-
2001: Alcindor T; Gorgun G; Miller K B; Roberts T F; Sprague K; Schenkein D P; Foss F M
Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease.
Blood 2001;98(5):1622-5.
-
2000: Roberts T F; Sprague K; Schenkein D; Miller K B; Relias V
Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
Blood 2000;96(12):4000-1.
-
2000: Schenkein D P; Koc Y; Alcindor T; Stadtmauer E A; Miller K B; Cooper B W; Partridge A H; Lazarus H M
Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2000;6(4A):448-55.
-
2000: Koc Y; Miller K B; Schenkein D P; Griffith J; Akhtar M; DesJardin J; Snydman D R
Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2000;6(1):44-9.
-
1999: Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Bone marrow transplantation 1999;24(5):473-81.
-
1999: Koc Y; Miller K B; Schenkein D P; Daoust P; Sprague K; Berkman E
Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation.
Cancer 1999;85(3):608-15.
-
1999: Jabro G; Koc Y; Boyle T; Schenkein D P; Ravalese J; Wazer D; Miller K B
Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1999;5(3):173-9.
-
1997: Schenkein D P; Roitman D; Miller K B; Morelli J; Stadtmauer E; Pecora A L; Cassileth P; Fernandez H; Cooper B W; Kutteh L; Lazarus H M
A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1997;3(4):210-6.
-
1996: McCann J C; Kanteti R; Shilepsky B; Miller K B; Sweet M; Schenkein D P
High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1996;2(1):37-43.
-
1995: Frenette P S; Desforges J F; Schenkein D P; Rabson A; Slapack C A; Miller K B
Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia.
American journal of hematology 1995;49(1):48-55.
-
1995: Mitus A J; Miller K B; Schenkein D P; Ryan H F; Parsons S K; Wheeler C; Antin J H
Improved survival for patients with acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):560-9.
-
1995: Comenzo R L; Malachowski M E; Miller K B; Erban J K; Schenkein D P; Desforges J F; Berkman E M
Large-volume leukapheresis for collection of mononuclear cells for hematopoietic rescue in Hodgkin's disease.
Transfusion 1995;35(1):42-5.
-
1994: Schenkein D P; Dixon P; Desforges J F; Berkman E; Erban J K; Ascensao J L; Miller K B
Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(11):2423-31.
-
1994: Miller K B; Schenkein D P; Comenzo R; Erban J K; Fogaren T; Hirsch C A; Berkman E; Rabson A
Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation.
Annals of hematology 1994;68(1):15-20.
-
1993: Miller K B; Schenkein D P
Hematology.
JAMA : the journal of the American Medical Association 1993;270(2):216-7.
-
1992: Comenzo R L; Malachowski M E; Miller K B; Erban J J; Schenkein D P; Desforges J F; Berkman E M
Engraftment with peripheral blood stem cells collected by large-volume leukapheresis for patients with lymphoma.
Transfusion 1992;32(8):729-31.
-
1992: Miller K B; Schenkein D P; Wasserman R L
Safety and tolerability of an intravenous immune globulin at various concentrations in 5% dextrose injection or sterile water for injection.
Clinical pharmacy 1992;11(7):628-31.
-
1992: Miller K B; Schenkein D P; Fogaren T
An assessment of the safety and tolerability of immune globulin intravenous (human) Sandoglobulin prepared in sterile water or 5% dextrose at various concentrations.
Seminars in hematology 1992;29(3 Suppl 2):109-11.
-
1991: Hillyer C D; Comenzo R L; Miller K B; Schenkein D P; Tiegerman K O; Fogaren T A; Wazer D E; Parker L; Abrams R A; Desforges J F
Prompt engraftment using autologous peripheral blood stem cells for double autologous bone marrow rescue.
American journal of hematology 1991;36(2):152-3.
-
1986: Schenkein D P; O'Neill W C; Shapiro J; Miller K B
Accelerated bone formation causing profound hypocalcemia in acute leukemia.
Annals of internal medicine 1986;105(3):375-8.
Sign-in to see more
